论文部分内容阅读
目的探讨脑苷肌肽联合低分子肝素钙用于急性脑梗死治疗的疗效与安全性。方法将116例急性脑梗死患者随机分为两组:脑苷肌肽联合低分子肝素钙治疗的58例为观察组,单用低分子肝素钙治疗的58例为对照组,进行对比研究,治疗2周后进行神经功能缺损评分。结果治疗后两组神经功能缺损评分有不同程度恢复,观察组改善幅度优于对照组,观察组基本治愈24例(41.38%)、显著进步19例(32.76%)、进步12例(20.69%),总有效55例(94.83%);对照组基本治愈11例(18.96%),显著进步14例(24.14%)、进步17例(29.31%),总有效42例(72.41%),两组比较差异有统计学意义(P<0.05)。两组均无明显不良反应发生。结论脑苷肌肽联合低分子肝素钙治疗急性脑梗死有较好的疗效和安全性。
Objective To investigate the efficacy and safety of cerebroside and low molecular weight heparin in the treatment of acute cerebral infarction. Methods A total of 116 patients with acute cerebral infarction were randomly divided into two groups: 58 patients treated with cerebroside and low molecular weight heparin calcium were treated as the observation group, 58 patients treated with low molecular weight heparin alone as the control group, compared with 2 Weeks after neurological deficit score. Results After treatment, the scores of neurological deficit in both groups recovered to some extent. The improvement rate of the observation group was better than that of the control group. The observation group was basically cured in 24 cases (41.38%), significantly improved in 19 cases (32.76%), improved in 12 cases (20.69% , And the total effective rate was 55 (94.83%). The control group was basically cured in 11 cases (18.96%), significantly improved in 14 cases (24.14%), advanced in 17 cases (29.31%) and total effective in 42 cases (72.41% The difference was statistically significant (P <0.05). No significant adverse reactions occurred in both groups. Conclusion Cerebroside glycosides combined with low molecular weight heparin in the treatment of acute cerebral infarction have good curative effect and safety.